ABOUT US YOUR HEALTH SCIENCE & INNOVATION OUR RESPONSIBILITY | CAREERS INVESTORS MEDIA EN SPECIALTY CARE Sanofi Genzyme Humanitarian Aid Programs Home Our responsibility Healthcare for all Sanofi Genzyme Humanitarian Aid Programs Akash, Gaucher disease, India Sanofi Genzyme’s Rare Humanitarian Program is the first humanitarian initiative of its kind for people with lysosomal storage disorders – a group of rare genetic conditions caused by enzyme deficiencies. The program provides access to free treatments for patients who meet the program’s criteria who otherwise would not have access to such treatments. Established in 1991 when our first treatment for Gaucher disease was approved by the U.S. FDA, the program has evolved and expanded to support five dierent lysosomal storage disorder communities, including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidoses (MPS) I and II across six continents. Over the past 30 years, our program has helped improve the health and lives of thousands of people with rare diseases across the globe – each with a personal story to share. EXPLORE THEIR STORIES OF HOPE AND IMPACT Each patient story reflects the real-life experiences of individuals diagnosed with one of the five lysosomal storage disorders noted. Individual patients may experience these diseases differently. 3,200+ patients treated in 100+ countries since the program began 375+ patients have received free therapy for 10+ years 900+ patients in 70+ countries receive free therapy Rare blood disorders (hemophilia) Sanofi’s humanitarian program for hemophilia is critical as a vast majority of people with this disease have limited or no access to diagnosis and treatment, and many in the developing world often don’t survive to adulthood. Together with Sobi™, Sanofi recently expanded its support of the World Federation of Hemophilia (WFH) Humanitarian Aid Program by pledging to donate up to an additional 500 million IUs of factor therapy for up to five years. This brings the total commitment up to an unprecedented 1 billion IUs for humanitarian use-the single largest donation of hemophilia factor therapy in history. With Sobi, Sanofi has delivered 538 million IUs to the WFH Humanitarian Aid Program since 2015. More than 17,300 patients in 45 contries have been treated through its donation. Partnerships for humanitarian aid Sanofi relies on its partners’ local expertise and relationships to help support patients and navigate the challenges of reaching them in countries around the world. Project HOPE ANERA (American Near East Refugee Aid) Direct Relief World Federation of Hemophilia Humanitarian Aid Program, and others. Related stories 20 Years of Humanitarian Support in China: Zhengtao’s Story READ THE STORY 27 Years of Humanitarian Programs in Vietnam READ THE STORY Sanofi Genzyme’s Humanitarian Programs Help Patients Worldwide READ THE STORY Transforming Humanitarian Aid in Hemophilia READ THE STORY Providing Hope to the Hemophilia Community in Kenya READ THE STORY MAT-GLB-2100856-v1.0-03/2021 Follow us Sanofi on Twitter Sanofi TV on YouTube Sanofi On LinkedIn Sanofi on Instagram Sanofi RSS feeds Contact Legal notice Privacy & Data Protection Cookies policy Corporate code of ethics Our publications Sitemap Our websites Accessibility: partial compliance © Sanofi 2004-2021 - All rights reserved Your privacy is important to us By clicking “Accept All” , you agree to the storing of cookies on your device to enhance site navigation, measure site performance and show you personalized advertising. You can manage individual cookies preferences or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third-parties intervening on our website, please consult the Cookies Policy, available in the site footer. Cookies settings Reject all Accept all